Cortisol and the Heart. Where the Evidence Is Solid and Where It Is Oversold.

Cortisol is the most discussed hormone in the wellness space and one of the most misunderstood in the clinical one. The cardiovascular mechanisms are real, the population-level associations are meaningful, and the supplement market built around this topic is running far ahead of the evidence. This article separates those three things.

The Mechanism

Cortisol is a glucocorticoid produced by the adrenal cortex. It does not originate there. It originates in a cascade. The hypothalamus releases corticotropin-releasing hormone (CRH). CRH signals the anterior pituitary to release adrenocorticotropic hormone (ACTH). ACTH travels through the bloodstream to the adrenal glands and drives cortisol synthesis and secretion. This is the HPA axis, the hypothalamic-pituitary-adrenal axis, and it functions as a finely tuned alarm system with a built-in shutoff. Elevated cortisol feeds back to both the hypothalamus and pituitary to suppress further CRH and ACTH release. The alarm turns itself off.

The clinical problem is not the alarm. It is what happens when the shutoff mechanism is chronically overridden.

Acute cortisol elevation is adaptive. A cortisol surge mobilizes glucose for immediate use, sharpens attention, suppresses non-essential immune activity, and elevates blood pressure to support perfusion during physical challenge. These effects last minutes to a few hours. When the stressor resolves, the negative feedback loop restores baseline. The system is designed to be episodic.

Cortisol chronicity is a different physiological state. When the stressor is not a single event but a sustained condition, the HPA axis remains in a low-level active state for months or years. The shutoff mechanism becomes less efficient. Morning cortisol peaks flatten. Nighttime cortisol, which should be near zero, remains elevated. The diurnal rhythm loses its amplitude. This flattened curve is not a minor variation. It is a measurable physiological signature with distinct cardiovascular consequences.

Blood pressure. Cortisol acts on both glucocorticoid and mineralocorticoid receptors. Through mineralocorticoid receptor activation in the kidney, even in the absence of elevated aldosterone, cortisol drives sodium and water retention. This increases plasma volume. Simultaneously, chronic cortisol sensitizes vascular smooth muscle to catecholamines like norepinephrine, increasing vascular tone. The net effect is persistent blood pressure elevation that does not respond simply to sodium restriction because the driver is hormonal, not dietary.

Visceral adiposity. Glucocorticoid receptors are expressed throughout adipose tissue, but omental fat, the visceral depot inside the abdominal cavity, expresses them at particularly high density. Cortisol preferentially activates lipogenesis in this compartment while simultaneously impairing lipolysis in a pattern that causes net fat accumulation centrally. Epel et al., publishing in Psychosomatic Medicine in 2000, demonstrated that women with greater cortisol reactivity to a laboratory stressor had significantly more visceral fat, controlling for total body mass. Rosmond and Bjorntorp, in a series of papers through the late 1990s and early 2000s, established the link between HPA axis dysregulation, abdominal obesity, and the metabolic syndrome. Visceral fat is not inert storage. It is an endocrine organ that produces inflammatory cytokines, free fatty acids, and adipokines that drive insulin resistance and dyslipidemia independently.

Endothelial dysfunction. The endothelium is the single-cell-thick lining of every blood vessel in the body. Its health depends substantially on its ability to produce nitric oxide via endothelial nitric oxide synthase (eNOS). Nitric oxide dilates vessels, inhibits platelet aggregation, and suppresses smooth muscle proliferation. Chronic glucocorticoid exposure reduces eNOS expression and activity, diminishing nitric oxide bioavailability. At the same time, cortisol promotes the production of reactive oxygen species and inflammatory cytokines, particularly IL-6 and TNF-alpha, which further impair endothelial function and promote the inflammatory signaling that drives atherosclerotic plaque development and progression.

Insulin resistance and dyslipidemia. Cortisol opposes insulin action directly. It promotes hepatic gluconeogenesis, reduces peripheral glucose uptake, and increases circulating free fatty acids through lipolysis in peripheral fat depots. The resulting insulin resistance drives compensatory hyperinsulinemia, which further promotes visceral fat accumulation and raises triglycerides while lowering HDL cholesterol. This is the same lipid pattern that defines atherogenic dyslipidemia and it clusters with elevated waist circumference in ways that are not coincidental.

Sleep disruption and nocturnal blood pressure. Cortisol’s diurnal rhythm normally creates a permissive window for sleep during its nadir. When cortisol remains elevated at night, sleep architecture is disrupted. Slow-wave sleep, the most restorative stage, is particularly sensitive to nocturnal glucocorticoid exposure. Disrupted sleep architecture is independently associated with cardiovascular risk through multiple pathways. Additionally, healthy sleep normally produces a nocturnal dip in blood pressure of 10 to 20 percent. Non-dippers, people whose blood pressure does not fall overnight, have significantly higher cardiovascular event rates. Chronic cortisol elevation is one mechanism by which this dipping pattern is lost.

Direct myocardial effects. Cardiac tissue expresses glucocorticoid receptors. Sustained glucocorticoid exposure at supraphysiologic levels, as seen in Cushing’s syndrome, produces cardiac remodeling including left ventricular hypertrophy and fibrosis. Whether the lower-level chronic elevation characteristic of chronic stress produces similar effects at the tissue level in humans is less clearly established. The Cushing’s data establishes the pathway exists. Extrapolation to chronic stress-related elevation is mechanistically plausible but not yet confirmed in well-powered human studies, which is a key reason the rating here is 4/Promising rather than 5/Solid.

It is important to be explicit about where this mechanistic knowledge comes from. The most detailed human mechanistic data on cortisol and the cardiovascular system comes from Cushing’s syndrome, a condition of pathological cortisol excess, either from an adrenal tumor, a pituitary adenoma, or exogenous steroid use. In Cushing’s syndrome, essentially every cardiovascular risk marker is elevated. Pivonello et al., reviewing this literature in Endocrine in 2012, documented the high prevalence of hypertension, visceral obesity, dyslipidemia, insulin resistance, and accelerated atherosclerosis in Cushing’s patients. These patients have cortisol levels that are dramatically elevated, not the modest chronic elevations characteristic of occupational or relational stress. The extrapolation from pathological cortisol excess to the chronic low-level activation of the stress response is biologically plausible but represents an inferential step that the evidence does not yet fully support with interventional data.

What the Evidence Shows

The most compelling epidemiological evidence comes from the Whitehall II study, a long-running prospective cohort following British civil servants. Kumari et al., publishing in the Journal of Clinical Endocrinology and Metabolism in 2011, analyzed diurnal salivary cortisol slopes in participants and found that a flattened diurnal cortisol slope, meaning a smaller difference between morning and evening levels, was associated with increased all-cause and cardiovascular mortality over follow-up. The key finding is what was measured: not a single cortisol level on a single morning, but the shape of the daily rhythm across multiple measurement days. A flat slope is the signature of a system that has lost its healthy pulsatility. This is what chronic load does, and it predicted cardiovascular death in a well-characterized population.

Steptoe and Wardle, also working with Whitehall II data and publishing in Psychoneuroendocrinology in 2005, examined cortisol awakening response, the sharp rise in cortisol that occurs in the first 30 to 45 minutes after waking in healthy individuals. A blunted awakening response, another marker of HPA axis dysregulation, was associated with adverse health outcomes and poorer functional status.

Vogelzangs et al., publishing in Depression and Anxiety in 2010, examined urinary cortisol levels in a large cohort and found that higher 24-hour urinary free cortisol was associated with a significantly increased risk of atherosclerosis and metabolic syndrome components. The association with cortisol and cardiovascular risk markers held after adjustment for depression, which is important because depression is an independent cardiovascular risk factor and a confound in this literature.

Reynolds et al., in a meta-analysis of diurnal cortisol slopes and mortality published in Psychoneuroendocrinology in 2018, synthesized data across multiple prospective cohort studies and confirmed the association between flatter slopes and increased mortality, including cardiovascular mortality. Effect sizes were modest to moderate, not trivial, but also not the dominant risk factor in any individual analysis.

The Cushing’s syndrome literature, as reviewed by Pivonello, Arnaldi, and others in multiple Endocrine journals between 2010 and 2015, provides the strongest evidence for a causal relationship between sustained cortisol excess and cardiovascular pathology. Untreated Cushing’s patients have dramatically elevated rates of myocardial infarction, stroke, and cardiac death compared to age-matched controls. When Cushing’s syndrome is successfully treated and cortisol normalized, cardiovascular risk markers improve substantially. This is as close to a natural experiment on cortisol causality as exists in human medicine.

What the evidence does not contain is a randomized controlled trial in which an intervention specifically reduced cortisol and the primary endpoint was cardiovascular events. That trial does not exist. The mechanistic data is strong. The population-level associations are consistent. The Cushing’s data supports causality at the high-cortisol extreme. But the specific hypothesis that reducing chronic low-level cortisol activation through any intervention reduces cardiovascular events in non-Cushing adults has not been tested in an adequately powered RCT. This gap is not a minor methodological footnote. It is the reason the evidence ceiling is 4/Promising.

What the evidence actively contradicts is the claim, common in supplement marketing, that specific cortisol-lowering supplements have documented cardiovascular benefits. Phosphatidylserine has small studies showing blunted cortisol response to laboratory stressors, none with cardiovascular endpoints. Ashwagandha has a handful of small trials showing modest reductions in self-reported stress and salivary cortisol, published in journals of varying rigor, with no cardiovascular outcome data. The supplement industry has identified a real mechanism, the cardiovascular consequences of HPA axis dysregulation, and built a market around it that the clinical evidence does not support.

What to Do This Week

1. Assess cortisol through its rhythm, not a single number. If you want meaningful information about your HPA axis function, ask your physician for a diurnal salivary cortisol series: samples collected at waking, 30 minutes after waking (to capture the cortisol awakening response), noon, evening, and bedtime. The shape of the curve matters more than any individual value. Alternatively, a 24-hour urinary free cortisol gives a reliable integrated output measure. A single morning serum cortisol, the most commonly ordered test, tells you almost nothing about chronic activation.

2. Use sleep quality as a cortisol proxy. You do not need a lab test to identify a disrupted diurnal rhythm. Waking unrefreshed after adequate sleep duration, difficulty falling or staying asleep, waking between 2 and 4 AM with an alert, running mind: these are characteristic of elevated nocturnal cortisol. A validated tool like the PSQI (Pittsburgh Sleep Quality Index) takes three minutes and gives you a reproducible score to track. If your score indicates poor sleep quality, that is a signal to investigate whether HPA axis dysregulation is a contributor.

3. Measure waist circumference, not just weight. Visceral fat, the depot most sensitive to chronic cortisol elevation, does not show up on a scale. It shows up in waist circumference. Measure at the level of the umbilicus, relaxed, not after exhaling maximally. A reading above 102 cm (40 inches) in men places you in the elevated risk category by established cardiometabolic criteria. This number, combined with fasting triglycerides and HDL, is more informative about your cortisol-related metabolic status than any single hormone measurement.

4. Apply skeptical evaluation to cortisol supplement claims. Before spending money on an adaptogen or cortisol-modulating supplement, ask two questions. First, what is the endpoint measured in the supporting trials? If it is salivary cortisol in a laboratory stress paradigm with 40 participants over 60 days, that is a mechanistic signal, not clinical evidence. Second, are there cardiovascular endpoint data? For every cortisol supplement currently marketed, the answer to the second question is no. That does not mean the supplement is harmful. It means the specific claim being made about cardiovascular protection is not supported by the evidence being cited.

5. Prioritize the interventions with actual evidence. Sustained aerobic exercise, meaning 150 minutes per week of moderate intensity or 75 minutes of vigorous intensity, has consistent evidence for reducing HPA axis reactivity, improving sleep architecture, reducing visceral fat, and lowering blood pressure. Each of these is a direct intervention on the cardiovascular consequences of cortisol chronicity. Consistent sleep, with a fixed wake time that anchors circadian rhythm, restores the diurnal cortisol pattern more effectively than any supplement studied. Reducing continuous cognitive demand, which means creating actual disconnection from work monitoring rather than nominal boundaries, reduces the sustained low-level HPA activation that drives chronic cortisol elevation. These three interventions are not glamorous. They do not have a product attached. The evidence for them is substantially better than for anything currently sold in the cortisol supplement space.

The mechanism linking cortisol chronicity to cardiovascular disease is real, well-described, and clinically significant. The supplement market built around it is operating ahead of the evidence. Those two statements are not in contradiction. Understanding which is which is what allows a man to act on what is actually supported, rather than on what is being sold to him.